Size | Price | Stock | Qty |
---|---|---|---|
1mg |
|
||
5mg |
|
||
10mg |
|
||
50mg |
|
||
100mg |
|
||
Other Sizes |
|
Targets |
HIV
|
---|---|
ln Vitro |
The fact that DDX3-IN-2's inhibitory potency decreases as RNA substrate concentrations rise indicates that it functions as a competitive inhibitor toward the substrate. When faced with the ATPase of DDX3, DDX1 helicase, and DENV NS3 helicase, DDX3-IN-2 is discovered to be entirely inactive[1].
|
ln Vivo |
Excellent biocompatibility is exhibited by DDX3-IN-2 (20 mg/kg; tail vein injection), and Wistar rats exhibit good tolerance to the 20 mg/kg dose[1]. Half-life elimination and plasmatic clearance values are rapidly eliminated by DDX3-IN-2 (10 mg/kg; IV bolus injection; 0~25 hours)[1].
|
Animal Protocol |
Animal/Disease Models: Wistar rats[1]
Doses: Tail vein injection Route of Administration: 20 mg/kg Experimental Results: Possessed excellent biocompatibility, and Wistar rats demonstrated a good tolerance to the dose of 20 mg/kg. Animal/Disease Models: Rats[1] Doses: Iv bolus injection (pharmacokinetic/PK Analysis) Route of Administration: 10 mg/kg; 0~25 hrs (hours) Experimental Results: Rapidly eliminated the half-life elimination and the plasmatic clearance values. |
References |
[1]. Brai A, et al. Human DDX3 protein is a valuable target to develop broad spectrum antiviral agents. Proc Natl Acad Sci U S A. 2016;113(19):5388-5393.
|
Molecular Formula |
C20H23N5O
|
---|---|
Molecular Weight |
349.43
|
CAS # |
1919828-81-1
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
SMILES |
N(C1=CC=C(N2C=C(CCCC)N=N2)C=C1)C(NC1=CC=CC=C1C)=O
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : 100 mg/mL (286.18 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.15 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.8618 mL | 14.3090 mL | 28.6180 mL | |
5 mM | 0.5724 mL | 2.8618 mL | 5.7236 mL | |
10 mM | 0.2862 mL | 1.4309 mL | 2.8618 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.